Oncodesign Services is a leading CRO specializing in drug discovery and preclinical services in oncology, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, and in vitro/in vivo pharmacology.
Products, services, technology
Integrated Drug Discovery & Medicinal Chemistry, Translational Pharmacology in Oncology & Immuno-Inflammation
DMPK & Bioanalysis: non-GLP/GLP, Pharmaco-imaging: Distribution, target engagement, and in vivo efficacy by multimodal translational imaging, Evaluation of microbiome in immunotherapies.
Cooperation possibilities
Seeking collaborators building preclincial proof-of-concept (PoC) packages in oncology, immuno-oncology, inflammatory and infectious diseases or Integrated Drug Discovery programs through our DRIVE platform - from hit-finding to IND filing - applied to NCEs, biologics or radiotherapeutics.
- https://www.oncodesign-services.com/
- +33 3 80 78 82 60
- contact@oncodesign-services.com
- Emily Fang, Ph.D.
Some insights
Oncodesign was one of the pioneers in translational medicine in the CRO industry, with persistent focus over decades on building better platforms for drug discovery. We offer this rich experience to all our collaborators in their fight for better medicines and treatments.
Very proud & inspired by our team of discovery scientists and drug developers who have really been on the frontlines bringing therapies from target to clinic. Also the long-term relationships we have with collaborators all over the world, seeing their programs from early stages come to fruition
An integrated and tightly knit team in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vitro and in vivo pharmacology
We focus heavily on science and technology, including protein degraders in the small molecules space, or chemistry around the manipulation of biologics.
We are scientists working hard to try to make people feel better and happier so they can spend more time with their families.
We strive to build a long-term, intimate network of collaborators and partnerships in Switzerland, to become an active participant and contributor in this privileged ecosystem, where so many innovations and the best discovery scientists and drug developers are congregated.
Biotech start-ups and companies in all stages of development and funding status, including academic research institutions and spin-outs
Mid-size or large Pharma looking to externalize research and development or extend capacity
Incubators and accelerators, early-stage funders in the ecosystem